The Delhi-based hospital chain Fortis Healthcare reported a 2.5% year-on-year decline in consolidated net profit for the September quarter of the fiscal year 2026-27 (Q2FY27). This decrease was attributed to an increase in general and tax expenses.
The company's net profit in Q2FY27 stood at 320 crore rupees, which is lower than the 329 crore rupees recorded in the same period last year. Fortis's operating expenses grew by 18.5% year-on-year, reaching 2,318 crore rupees in Q2FY27. Similarly, tax expenses increased to 111.84 crore rupees compared to 96.58 crore rupees in the same quarter of the previous year.
However, the net profit figure includes a smaller exceptional income of 3 crore rupees in Q2FY27, whereas it was 24 crore rupees in Q2FY26 due to the cancellation of impairment in an affiliated company. Excluding this exceptional item, Fortis's net profit for the September quarter increased by 4% year-on-year, reaching 317 crore rupees compared to 305 crore rupees the previous year.
On the other hand, the network's operating revenue grew by 17% to 2,735 crore rupees, up from 2,331 crore rupees in Q2FY26. The revenue growth is driven by strong results in both the hospital and diagnostic segments.
The hospital business demonstrated an 18.6% year-on-year revenue growth in Q2FY27, supported by improved occupancy rates and increased revenue from specialized areas. Occupancy reached 72%, up from 71% in Q2FY26. As stated by Fortis in its investor presentation, the number of occupied beds increased to 3,616 compared to 3,318 in Q2 FY26, representing a 9% increase. Specializations such as oncology, cardiology, and nephrology showed a revenue growth of 16.7% and accounted for 60% of the total hospital business revenue. Furthermore, revenue from international patients grew by 12.4% to 190 crore rupees in Q2FY27 compared to 169 crore rupees in Q2FY26.
The company's diagnostic business reported a 12.2% year-on-year revenue growth, reaching 448 crore rupees, linked to increased group revenue from the preventive portfolio.
Future plans of the company
Commenting on future intentions, Ashutosh Raguvanshi, Managing Director and CEO, stated that Fortis will remain committed to strengthening clinical capabilities and expanding its presence in key markets. As part of its organic growth strategy, Fortis is evaluating opportunities for strategic mergers and acquisitions (M&A), as well as Greenfield projects, including build-to-suit models (sale or lease), in established markets such as Mumbai, Kolkata, and Hyderabad. The company also noted in its investor presentation that it plans to target similar growth and expansion opportunities in select attractive and underserved Tier-2 regions across Central India and near its key clusters for further geographical reach.
The company aims to increase its bed capacity to 12,000 over the next three to five years. As of September 30, 2026, the group operated 6,300 beds across its network. The results were announced after the close of trading. On Thursday, Fortis Healthcare shares closed on the Bombay Stock Exchange (BSE) 3.68% lower, at 820 rupees.


